|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: Antidyslipidemics - Statins Hit the Brakes on Market Growth
Datamonitor, Dec 2005, Pages: 181
The antidyslipidemics market is driven by the statins, which account for 87% of it. However, as many statins are expected to face patent expiry in the coming decade their role is expected to change from a driver to that of almost a resistor. Manufacturers are looking to novel products to protect their franchise, such as Pfizers atorvastatin/torcetrapib.
Scope of this title:
- Country specific event-driven sales forecasts for the period 2005-14 for the US, Japan, France, Germany, Italy, Spain and the UK and Global overview
- Patient potential and prescribing trends overview in the antidyslipidemics market, based on historical sales data and future key events
- Profiles of the country and market-specific issues which will impact future sales, including generic erosion and class switching
- Case studies presenting Pfizers strategy with atorvastatin/torcetrapib to maintain the Lipitor franchise, and the impact of key clinical trials
Highlights of this title:
Increased knowledge of the metabolic syndrome, fears of statin side effects, and the increasing data on the importance of HDL have all served to drive growth of the adjunctive anti-dyslipidemic agent market, by creating an opportunity for novel as well as combination therapies.
Pfizers atorvastatin + torcetrapib combination is expected to have a major impact on the dyslipidemia market and is expected to compete with both atorvastatin and Vytorin (simvastatin + ezetimibe). While AstraZenecas Crestor is set to significantly increase in sales due to new safety data.
The expiration of key statin patents could lead to the shrinking of the market value. The situation will be salvaged by the growing classes of cholesterol uptake inhibitors and single pill combinations.
Reasons to order your copy:
- View independent, event-driven forecasts for key anti-dyslipidemic products and classes across the seven major markets
- Obtain key opinion leader comments on various topics including prescribing trends and opinions on currently marketed and late stage development drugs
- Identify the potential impact of clinical trial results, EU healthcare reform and new product launches on the antidyslipidemic market
Customers who bought this item also bought
Commercial Insight: Antidyslipidemics - The competitive cost-conscious antidyslipidemics market presents challenges
Antidyslipidemics - Cholesterol Absorption of Lipitors Dominance
Strategic Perspectives: Antidyslipidemics - Current Market is not Conducive for Growth
Commercial Insight: Antidyslipidemics - Branded Statins Beware, Generics Are Amongst You
Antidyslipidemics - The Power Of Two
Pipeline Insight: Antidyslipidemics - The Power of Two
Antidyslipidemics - Genericization and Negative Trial Data Drive Market Shrinkage
Forecast Insight: Dyslipidemia - Genericization and Negative Trial Data Drive Market Shrinking
Statin Adjunct Therapy - Zetia, Revenue Protection for Zocor?
Sector Snapshot: Statin Drug Markets
Market Dynamics: Anti-dyslipidemics - Third Generation Statins Superfluous to Market Requirements?
Dyslipidemia - Statins Dominate Treatment Pathway - For Now
|
|
|
|
